Gyre Therapeutics

GYRE

Market cap $675M

GYRE Hedge Fund Activity: Q1 2026 in Review

56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2026, worth a combined $23.8M — up 0.57% from $23.6M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GYRE positions and 2 closed out — a net gain of 13 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $326K. The largest seller was Morgan Stanley, cutting an estimated $356K.

• 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2026, up from 44 in Q4 2025.
• Funds reported $23.8M of Gyre Therapeutics stock for Q1 2026, up 0.57% quarter-over-quarter.
• 15 funds opened new Gyre Therapeutics positions in Q1 2026 and 2 closed out, a net change of +13 holders.
• The largest Gyre Therapeutics buyer in Q1 2026 was Goldman Sachs, an estimated $326K added.
• The largest Gyre Therapeutics seller in Q1 2026 was Morgan Stanley, an estimated $356K sold.

Based on aggregated 13F filings for Q1 2026.